RFA-DC-27-004: BRAIN Initiative Exploratory Research Opportunities Using Invasive Neural Recording and Stimulation in the Human Brain (R61)

RFA-DC-27-004: BRAIN Initiative Exploratory Research Opportunities Using Invasive Neural Recording and Stimulation in the Human Brain (R61)

At a glance

This is a real, active 2026 NIH funding call with a confirmed first deadline later this week of your current target date context, and a second 2027 submission date. It is one of the most technical and policy-heavy BRAIN Initiative opportunities, especially because it combines advanced invasive human research access with strict regulatory, ethics, and data-sharing obligations.

Why this opportunity is meaningful in 2026–2027

The NOFO is more than a standard neuroscience grant. It is explicitly designed around rare windows of scientific access: procedures where intracranial access naturally occurs during medical care. The value is not only money; it is the ability to test mechanistic hypotheses that are impossible in non-invasive or animal-only models.

The opportunity supports projects that explore dynamic neuronal activity and behavior at the scale of local circuits and broader networks. The description states that investigators should propose exploratory research and planning activities that establish feasibility for future larger projects. That means this is especially useful for teams ready to show disciplined, high-risk/high-reward planning around a strong question, not already-fully mature clinical trials.

If your group has existing clinical contacts, device access planning, and an interdisciplinary team model (clinicians, engineers, data scientists, computational experts, and ethics or regulatory support), this NOFO is aimed at that profile. It is less aligned with teams that want to run classical therapy trials or deliver immediate clinical interventions.

You can think of this as a bridge award: it expects scientific rigor and operational readiness now, with the explicit purpose of proving out feasibility that can support stronger future proposals in the same research line.

What the opportunity covers and explicitly excludes

The source NOFO gives a precise positioning of scope:

• invasive recording and/or stimulation studies in humans with direct intracranial access
• high-impact neuroscience questions rooted in clear, mechanistic hypotheses
• studies that can use rare surgical windows to test questions at single-cell, ensemble, or circuit scales
• projects that benefit from direct coordination with the BRAIN Initiative multisite framework

This is not a therapeutic trial mechanism. The call repeats that proposed projects must not be designed as clinical trials and does not intend disease-treatment efficacy work as a primary target. A few common misalignments to watch for:

• proposing studies with efficacy end points as the main objective
• positioning the project as general translational device development without human-mechanistic focus
• treating the NOFO as a funding mechanism for routine disease treatment comparisons

The NOFO also states that applications involving human subjects that are not clinical trials are acceptable when aligned with this framework. So it is possible to include human subjects components, but not conventional efficacy trials.

Budget, award size, and funding structure

This is an important section because many teams focus on science and miss compliance constraints early.

From the official announcement:

• NIH partner institutes estimate $6M in total costs to fund approximately five awards per receipt date.
• Application budgets may not exceed $700,000 in direct costs per year, excluding facilities and administrative costs for consortia.
• Project period is capped at 3 years, and scope should determine duration.

You do not get a single fixed total award cap in this NOFO; you get a budget rule that requires disciplined planning. For proposals that involve complex multi-site operations, this is a major planning constraint: budget lines for neurosurgical coordination, data storage, clinical collaboration, and ethics/compliance infrastructure must be justified without breaking the direct-cost ceiling.

Given the competitive and technically demanding nature, teams frequently underestimate:

1. patient recruitment or procedural access coordination costs,
2. data security and data management obligations,
3. ethics and monitoring workload tied to invasive neuroscience studies,
4. consortium management overhead and publication governance,
5. human-subjects documentation and review time.

If your current concept depends on a large device-development spend with external vendors, you should budget conservatively and document contingency plans.

Eligibility: who can apply and the critical constraints

The NOFO has unusually broad eligible organization classes. It includes higher education, nonprofits, small businesses, local and federal governments, and related U.S.-based entities. At the same time, it has hard restrictions that matter:

• Non-domestic foreign organizations are not eligible.
• Even U.S.-based applicants cannot include foreign subawards/subcontracts; this rule applies across grant administration.
• Foreign consultants and procurement of unique foreign equipment/supplies can still be possible in narrow forms, but funded foreign subawards are blocked.

In practical terms: if your team depends on direct money flow to a foreign partner institution as a subaward, you will be out of scope for this NOFO unless that is not the funding path.

For personnel, the call is also specific:

• PD(s)/PI(s) must have active eRA Commons accounts.
• PD(s)/PI(s) must have an ORCID and link it to eRA Commons profile.
• Multiple PI models are allowed but must follow NIH M-PD/PI policy.

No cost-sharing requirement is imposed, which helps, but does not reduce administrative requirements.

Registration and compliance prerequisites you must clear before writing

The NOFO repeatedly states that the application process starts before science writing.

Minimum institutional registrations usually include:

• SAM and active UEI
• eRA Commons with PI role setup
• institutional systems (if using system-to-system pathways)

The NOFO points out registration can take six weeks or more. In practice, teams that miss this window lose precious weeks before submission and then rush scientific sections. The first submission date for this cycle is 2026-06-09, so delaying registration puts you at real operational risk.

Submission channels are standard NIH pathways:

• NIH ASSIST, or
• institutional system-to-system, or
• Grants.gov Workspace.

The NOFO stresses strict conformance to the NIH Research (R) Instructions, and non-compliance can result in delayed processing or rejection.

Application process and practical timeline planning

Immediate pre-submission plan (7–10 weeks before deadline)

1. Confirm team lead commitment and institutional signing setup.
2. Verify eRA Commons and ORCID links for every PD/PI.
3. Decide whether your project fits the R61 exploratory intent or is better suited to a clinical, translational, or device-delivery mechanism.
4. Confirm all invasive-access assumptions are explicit and realistic.
5. Start drafting a one-page team management plan.

Core submission package focus

The strongest applications show three things clearly and early:

• A research question that absolutely needs direct intracranial access.
• A feasible operations plan for timing around a clinical opportunity (e.g., short-duration implanted windows).
• A plan that avoids the forbidden zone: no explicit clinical trial efficacy objective.

The NOFO requires a Team Management Plan as a separate 1-page PDF attachment. This is often treated as optional by weaker applicants, but it should be central to your score potential. It should include:

• governance structure,
• scientific steering model,
• communication cadence,
• authorship and publication policy,
• conflict-resolution processes.

Timeline details from the official key dates

The published key dates show this is currently active:

• Open: 2026-05-09
• First deadline: 2026-06-09 (AIDS 2026)
• Next deadline: 2027-02-11
• Expiration: 2027-02-12

Given these dates, the best strategy is to treat this as a short planning sprint for the first cycle and reserve the second cycle for revised strategy if needed.

What the review panel is likely to reward

The NOFO’s review section indicates the panel focuses on:

• scientific significance,
• innovation quality,
• rigor and feasibility,
• likely transition path to future grant scale-up,
• and how well the project uses limited invasive access windows.

Because this is an exploratory mechanism, reviewers are not expecting a fully mature clinical program, but they are expecting robust feasibility and a clear logic path from access to interpretable outcome.

A strong proposal usually does these well:

• translates theory into concrete hypotheses with measurable outputs,
• clearly explains why non-invasive alternatives are insufficient,
• shows interdisciplinary execution readiness,
• integrates neuroethical and patient-consent protections in detail,
• and addresses data governance expectations.

Reviewer risk points include:

• insufficiently specific hypotheses,
• weak study design and low feasibility,
• inconsistent plans for neuroethical review,
• weak consortium structure,
• missing or generic team management planning,
• lack of clarity on where and when intracranial access will occur.

Common mistakes and how to avoid them

1) Treating this as a clinical trial call

The title includes “Clinical Trial Not Allowed” for a reason. A common mistake is to keep disease-treatment endpoints as central claims. Keep the focus exploratory and feasibility-driven.

2) Underestimating registration and profile setup

Missing eRA Commons readiness or ORCID linking is avoidable and repeatedly causes late or blocked applications. Confirm PI profiles early and include them in your project management checklist.

3) Ignoring the no-foreign-subaward rule

Many multi-institution proposals accidentally build foreign financial subcontracting into the baseline design. This NOFO specifically rejects applications with foreign subawards/subcontracts.

4) Treating neuroethics as boilerplate

This call is ethically demanding because the work is invasive and human-centered. Reviewers and program staff expect explicit discussion of consent, risk communication, and post-study patient care planning.

5) Weak team management plan

You must include a dedicated PDF. A generic or superficial plan signals poor execution readiness. Include roles, conflict handling, meeting cadence, and publication policy.

6) Missing the one-page discipline

Even where other sections can be substantial, this specific attachment should be tightly scoped and practical.

Who this is best for

This opportunity is a fit if your team is already connected to invasive neuroscience infrastructure or has a realistic path to secure that access ethically and compliantly.

Useful applicant profile:

• PI with strong translational neuroscience understanding and institutional support.
• Technical partners with experience in device-based recordings or stimulation.
• computational lead able to pre-register and test analysis logic.
• ethics and regulatory partners who can move quickly.

This is likely a poor fit if:

• your team lacks an access pathway,
• project questions can be answered non-invasively,
• you are seeking late-stage clinical efficacy data,
• your budget assumption depends on high-cost external vendors not covered within the direct-cost cap.

Application preparation checklist (practical)

Use this as a pre-submission audit list:

1. Eligibility confirmed for organization and all key collaborators.
2. Foreign subcontracting assumptions removed or converted to compliant non-funded collaboration.
3. PI eRA Commons active and ORCID linked.
4. Team management plan drafted and assigned ownership.
5. Human subjects/clinical interface section states exactly what will be recorded, when, and how risk will be managed.
6. Neuroethical safeguards and long-term participant care logic included.
7. Data Management and sharing strategy defined with practical storage/transfer workflows.
8. Reviewer-facing narrative built around feasibility, not clinical outcome claims.
9. Budget checks complete against the $700,000 direct-cost annual limit.
10. Application submitted early enough to handle portal corrections.

Frequently asked questions

Is this still open?

As of the target date context (2026-05-31), this opportunity is open with a posted first submission deadline of 2026-06-09 and a later 2027-02-11 intake.

Is this an NIH R61 grant?

Yes. The activity code is R61, which in this case is used for exploratory/developmental human neuroscience work that can feed a later larger project if feasibility is demonstrated.

How much can we request?

The official ceiling is $700,000 direct costs per year. Total commitments are estimated across the cycle, with about $6M total costs announced for approximately five awards per receipt date.

Can an organization outside the United States apply?

No. The opportunity is for domestic U.S. applicants and specifically excludes non-domestic entities as primary awardees. There are rules against foreign subawards, so financial collaboration with foreign institutions is heavily constrained.

Is a pilot clinical trial allowed if it is small-scale?

No. The mechanism is explicitly “Clinical Trial Not Allowed,” and the NOFO emphasizes non-therapeutic, exploratory research in this framework.

Can small businesses apply?

Small businesses are listed as eligible organizations in the eligible applicant classes.

What should be in the team management plan?

A clear structure for governance, communications, leadership roles, conflict resolution, and authorship decisions. It should also show how the multidisciplinary team coordinates in practice.

Review and risk management: reviewer-facing quality signals

Strong applicants typically show that they can operate like a small, high-complexity translational machine.

• Feasibility is judged, not just excitement. A question with high concept value but weak operational mapping often scores poorly.
• Multidisciplinary coherence matters. Listing team members is insufficient; review panels assess whether the collaboration model is executable.
• Timeline realism is crucial for invasive-access work because patients and procedural windows are constrained.
• Neuroethical detail is now central to competitive scoring.

Official links and source references

• Full announcement: https://files.simpler.grants.gov/opportunities/29cb8db4-585f-4e67-a21e-235ec9bf6829/attachments/310afbc6-56c4-4793-8dd5-e7b32362a9ef/RFA-DC-27-004-Full-Announcement.html
• NIH Grants Guide (application instructions): https://grants.nih.gov/grants/how-to-apply-application-guide
• Grants policy and updates: https://grants.nih.gov/grants/policy
• NIH BRAIN Initiative overview for context (non-authoritative for this call specifics): https://www.braininitiative.nih.gov/

Final assessment and next steps

This is one of the more technically demanding but strategically useful 2026/2027 NIH neuroscience opportunities, especially if your group has credible access to real invasive neural recording contexts and is prepared to run a disciplined exploratory program.

Use this opportunity for projects that are conceptually strong, feasible within narrow time windows, and designed to generate the kind of validated pilot evidence needed for a second-stage application.

If your current work already depends on invasive procedures and robust cross-disciplinary collaboration, this is a good call to prioritize now. If you are still defining access logistics, the 2027 intake can be your fallback, but the safest path is to begin registration, ethics planning, and team governance immediately so your next draft is not blocked by admin requirements.